公开(公告)号：US20250009737A1

公开(公告)日：2025-01-09

申请号：US18759774

申请日：2024-06-28

Applicant: Arvinas Operations, Inc.

Inventor： Jingang George ZHANG ,  Lawrence B. SNYDER ,  Yongqing HUANG

IPC: A61K31/496 ,  A61K45/06

Abstract: This disclosure pertains to methods of treating prostate cancer in a subject in need thereof, including, for example, metastatic prostate cancer, castrate-resistant prostate cancer, and metastatic castrate-resistant prostate cancer, wherein the method comprises administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and further comprises a step of discontinuing or reducing the administration of a CYP3A inhibitor or inducer, an efflux transporter substrate or inhibitor, or an uptake transporter substrate or inhibitor, to the subject prior to initiating administration of Compound A or the pharmaceutically acceptable salt thereof.

公开(公告)号：US20210353621A1

公开(公告)日：2021-11-18

申请号：US17317235

申请日：2021-05-11

Applicant: Arvinas Operations, Inc.

Inventor： Ronald PECK ,  Yongqing HUANG ,  Chi Fung KEUNG

IPC: A61K31/497 ,  A61K31/506 ,  A61K31/496 ,  A61K31/501 ,  A61P35/00

Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.